Atossa Therapeutics
ATOS
86 hedge funds and large institutions have $28.3M invested in Atossa Therapeutics in 2024 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 29 increasing their positions, 23 reducing their positions, and 9 closing their positions.
954% more capital inflows, than outflows
Capital inflows: $3.72M | Capital outflows: $353K
59% more call options, than puts
Call options by funds: $165K | Put options by funds: $104K
26% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 23
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
2.05% more ownership
Funds ownership: 21.74% → 23.79% (+2.1%)
0% more funds holding
Funds holding: 86 → 86 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.37M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$346K |
| 3 |
Renaissance Technologies
New York
|
+$322K |
| 4 |
JP Morgan Chase
New York
|
+$275K |
| 5 |
VF
Virtu Financial
New York
|
+$205K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
-$59.8K |
| 2 |
Wolverine Trading
Chicago,
Illinois
|
-$40.2K |
| 3 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
-$36.4K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$22K |
| 5 |
LPL Financial
San Diego,
California
|
-$20.8K |
ATOS Hedge Fund Activity: Q4 2024 in Review
86 of the 7,614 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q4 2024, worth a combined $28.3M — down 32% from $41.6M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ATOS positions and 9 closed out — a net gain of 2 holders — while 29 added to existing stakes and 23 trimmed.
The largest buyer was UBS Group, adding an estimated $1.37M. The largest seller was Charles Schwab, cutting an estimated $59.8K.
- 86 institutional investors held Atossa Therapeutics (ATOS) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $28.3M of Atossa Therapeutics stock for Q4 2024, down 32% quarter-over-quarter.
- 11 funds opened new Atossa Therapeutics positions in Q4 2024 and 9 closed out, a net change of +2 holders.
- The largest Atossa Therapeutics buyer in Q4 2024 was UBS Group, an estimated $1.37M added.
- The largest Atossa Therapeutics seller in Q4 2024 was Charles Schwab, an estimated $59.8K sold.
Based on aggregated 13F filings for Q4 2024.